| Literature DB >> 29172395 |
Yangkyu Lee1, Hyunjin Park2, Hyejung Lee2, Jai Young Cho3, Yoo-Seok Yoon3, Young-Rok Choi3, Ho-Seong Han3, Eun Sun Jang4, Jin-Wook Kim4, Sook-Hyang Jeong4, Soomin Ahn1, Haeryoung Kim2.
Abstract
BACKGROUND: We aimed to determine the clinicopathological significance of the gross classification of hepatocellular carcinoma (HCC) according to the Korean Liver Cancer Association (KLCA) guidelines.Entities:
Keywords: Carcinoma, hepatocellular; Gross classification; Prognosis
Year: 2017 PMID: 29172395 PMCID: PMC5859242 DOI: 10.4132/jptm.2017.11.13
Source DB: PubMed Journal: J Pathol Transl Med ISSN: 2383-7837
Fig. 1.Examples of the different gross types of hepatocellular carcinoma. (A) Vaguely nodular type. (B) Expanding nodular type. (C) Multinodular confluent type. (D) Nodular with perinodular extension type. (E) Infiltrative type.
Summary of the clinicopathological characteristics
| Characteristic | No. (%) (n = 242) |
|---|---|
| Sex | |
| Male | 181 (74.8) |
| Female | 61 (25.2) |
| Age at operation, median (range, yr) | 59 (29-87) |
| Preoperative serum AFP level, median (range, ng/mL) | 14.35 (1–40,000) |
| Etiology | |
| Hepatitis B virus (HBV) | 171 (70.7) |
| Alcohol | 35 (14.5) |
| Hepatitis C virus (HCV) | 17 (7.0) |
| HBV + HCV | 1 (0.4) |
| Uncertain etiology | 18 (7.4) |
| Tumor size, median (range, cm) | 3.0 (0.9–17.0) |
| ≤ 2 | 52 (21.5) |
| > 2 and ≤ 5 | 145 (59.9) |
| > 5 | 45 (18.6) |
| Gross type | |
| Vaguely nodular | 9 (3.7) |
| Expanding nodular | 107 (44.2) |
| Multinodular confluent | 78 (32.2) |
| Nodular with perinodular extension | 32 (13.2) |
| Infiltrative | 16 (6.6) |
| Edmondson-Steiner grade | |
| Grade I | 2 (0.8) |
| Grade II | 74 (30.6) |
| Grade III | 142 (58.7) |
| Grade IV | 24 (9.9) |
| Microvascular invasion | |
| Absent | 154 (63.6) |
| Present | 88 (36.4) |
| Portal vein invasion | |
| Absent | 225 (93.0) |
| Present | 17 (7.0) |
| Cirrhosis in background liver | |
| Absent | 109 (45.0) |
| Present | 126 (52.1) |
| Intratumoral fibrous stroma (> 30%) | |
| Absent | 187 (77.3) |
| Present | 55 (22.7) |
| Pathologic T category (AJCC 7th edition) | |
| pT1 | 140 (57.9) |
| pT2 | 82 (33.9) |
| pT3 | 17 (7.0) |
| pT4 | 3 (1.2) |
| Pathologic N category (AJCC 7th edition) | |
| pN0 | 240 (99.2) |
| pN1 | 2 (0.8) |
| Recurrence on follow-up | |
| Absent | 138 (57.0) |
| Present | 104 (43.0) |
| Status at last follow-up | |
| Alive | 160 (66.1) |
| Deceased of disease | 19 (7.9) |
| Deceased of other cause | 5 (2.1) |
| Follow-up loss | 58 (24.0) |
AFP, α-fetoprotein; AJCC, American Joint Committee on Cancer.
Clinicopathological features and immunohistochemical stain results according to gross type
| VN (n = 9) | EN (n = 107) | MC (n = 78) | NP (n = 32) | INF (n = 16) | Type 1 (VN, EN) (n = 116) | Type 2 (MC, NP, INF) (n = 126) | p-value (type 1 vs 2) | |
|---|---|---|---|---|---|---|---|---|
| Tumor size (> 5 cm) | 0 | 11 (10.3) | 21 (26.9) | 7 (21.9) | 6 (37.5) | 11 (9.5) | 34 (27.0) | < .001 |
| HBV etiology | 5 (55.6) | 73 (68.2) | 58 (74.4) | 21 (65.6) | 15 (93.8) | 78 (67.2) | 94 (74.6) | .207 |
| Edmondson-Steiner grade III/IV | 4 (44.4) | 64 (59.8) | 58 (74.4) | 25 (78.1) | 15 (93.8) | 68 (58.6) | 98 (77.8) | .001 |
| Microvascular invasion | 1 (11.1) | 29 (27.1) | 34 (43.6) | 14 (43.8) | 10 (62.5) | 30 (25.9) | 58 (46.0) | < .001 |
| Portal vein invasion | 0 | 0 | 4 (5.1) | 5 (15.6) | 8 (50.0) | 0 | 17 (13.55) | < .001 |
| High T category (pT3 or pT4) | 0 | 1 (0.9) | 7 (9.0) | 5 (15.6) | 7 (43.8) | 1 (0.9) | 19 (15.1) | < .001 |
| Cirrhosis in background liver | 6 (66.7) | 49 (46.7) | 42 (57.5) | 15 (46.9) | 14 (87.5) | 55 (48.2) | 71 (58.1) | .118 |
| Serum AFP level > 1,000 ng/mL | 0 | 12 (13.6) | 10 (14.7) | 6 (20.7) | 6 (37.5) | 12 (12.6) | 22 (19.5) | .194 |
| Fibrous stroma (> 30%) | 1 (11.1) | 14 (13.1) | 25 (32.1) | 9 (28.1) | 6 (37.5) | 15 (12.9) | 40 (31.7) | < .001 |
| CK19 positive | 2 (22.2) | 10 (9.3) | 20 (25.6) | 7 (21.9) | 6 (37.5) | 12 (10.3) | 33 (26.2) | .002 |
| EpCAM positive | 3 (33.3) | 37 (34.6) | 34 (43.6) | 19 (59.4) | 12 (75.0) | 40 (34.5) | 65 (51.6) | .009 |
| uPAR positive | 1 (11.1) | 16 (15.2) | 22 (28.2) | 14 (43.8) | 12 (75.0) | 17 (14.9) | 48 (38.1) | < .001 |
| Ezrin positive | 4 (44.4) | 34 (32.4) | 40 (51.3) | 12 (37.5) | 7 (43.8) | 38 (33.3) | 59 (46.8) | .036 |
VN, vaguely nodular; EN, expanding nodular; MC, multinodular confluent; NP, nodular with perinodular extension; INF, infiltrative; HBV, hepatitis B virus; AFP, α-fetoprotein; CK19, cytokeratin 19; EpCAM, epithelial cell adhesion molecule; uPAR, urokinase plasminogen activator receptor.
Fig. 2.Immunohistochemical stain results for stemness- and epithelial-mesenchymal transition-related markers: cytokeratin 19 (A), epithelial cell adhesion molecule (B), and ezrin (C).
Survival analysis results
| Variable | Overall survival | Disease-free survival | ||
|---|---|---|---|---|
| Hazard ratio (95% confidence interval) | p-value | Hazard ratio (95% confidence interval) | p-value | |
| Univariate analysis | ||||
| Gross type (type 1 vs type 2)[ | 5.439 (1.583–18.683) | .007 | 1.617 (1.092–2.394) | .016 |
| Tumor size (> 5 cm) | 1.229 (0.407–3.712) | .714 | 1.590 (1.013–2.495) | .044 |
| High E-S grade (III or IV) | 0.636 (0.256–1.583) | .331 | 1.054 (0.694–1.599) | .805 |
| Microvascular invasion | 2.178 (0.881–5.383) | .092 | 1.445 (0.977–2.138) | .065 |
| Portal vein invasion | 5.311 (1.906–14.796) | < .001 | 1.702 (0.858–3.376) | .128 |
| High T category (pT3 or pT4) | 5.206 (1.974–13.728) | < .001 | 1.795 (0.982–3.284) | .057 |
| Intratumoral stromal fibrosis | 2.037 (0.801–5.179) | .135 | 0.973 (0.608–1.559) | .973 |
| Multivariate analysis | ||||
| Gross type (type 1 vs type 2) | 4.118 (1.142–14.844) | .030 | 1.617 (1.092–2.394) | .016 |
| Tumor size (> 5 cm) | 0.586 (0.166–2.060) | .404 | 1.303 (0.802–2.115) | .285 |
| Microvascular invasion | 1.953 (0.765–4.982) | .161 | 1.300 (0.866–1.952) | .205 |
| Portal vein invasion | 1.091 (0.150–7.931) | .931 | 0.954 (0.292–3.124) | .938 |
| High T category (pT3 or pT4) | 3.173 (1.156–8.710) | .025 | 1.462 (0.500–4.275) | .487 |
E-S grade, Edmondson-Steiner grade.
Type 1: vaguely nodular and expanding nodular types, type 2: multinodular confluent, nodular with perinodular extension and infiltrative types.
Fig. 3.Kaplan-Meier curves demonstrating differences in disease-free survival and overall survival according to gross classification of hepatocellular carcinoma. (A, B) Disease-free survival. (C, D) Overall survival. VN, vaguely nodular; EN, expanding nodular; MC, multinodular confluent; NP, nodular with perinodular extension; INF, infiltrative.